Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
PREVISS
2 other identifiers
interventional
60
1 country
1
Brief Summary
Systemic sclerosis is a rare autoimmune disorder characterized by microangiopathy, activation of the immune system, and sclerosis of tissues including the skin. Facial involvement is frequent and disabling. It causes significant functional and aesthetic discomfort, and a major deterioration in quality of life. It results in a loss of suppleness of the skin and subcutaneous tissues, dysfunction of the temporomandibular joint, peribuccal rhagades, microstomia, and dry mouth causing difficulties in mouth opening, feeding, dental care, and weight loss. Facial involvement in systemic sclerosis can be assessed using the Mouth Handicap in Systemic Sclerosis (MHISS) score, a validated patient questionnaire assessing the functional and aesthetic consequences of systemic sclerosis on the face. Although common and disabling, facial involvement is underestimated and poorly managed. Immunosuppressive and/or anti-fibrosis drugs are not very effective. Facial rehabilitation could significantly improve the mouth handicap but facial rehabilitation is not currently performed in standard care in systemic sclerosis patients. The aim of the study is to evaluate the efficacy of a personalized rehabilitation program vs standard care in facial involvement of systemic sclerosis patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 22, 2021
CompletedFirst Posted
Study publicly available on registry
January 4, 2022
CompletedStudy Start
First participant enrolled
October 13, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2029
June 8, 2026
June 1, 2026
7.1 years
November 22, 2021
June 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mouth Handicap In Systemic Sclerosis (MHISS) score
A 12-item questionnaire specifically quantifying mouth disability in systemic sclerosis
Week 6
Secondary Outcomes (18)
Mouth Handicap In Systemic Sclerosis (MHISS) score
Week 2
Mouth Handicap In Systemic Sclerosis (MHISS) score
Week12
Interincisal distance measurement
Week 6
Interincisal distance measurement
Week 12
Rodnan skin score on the face
Week 6
- +13 more secondary outcomes
Study Arms (2)
Personalized rehabilitation program of facial involvement in systemic sclerosis
EXPERIMENTAL3 sessions of 2 hours of facial rehabilitation in hospital over 2 weeks including: * Physiotherapy with facial and endo-oral massages, self-massages, active and passive exercises of the face and mouth, tongue exercises * Speech therapy with mobilization of the orofacial sphere applied to swallowing and speech difficulties * Individual workshop on the theme of dry mouth, dry mouth, swallowing disorders, and oral care * Individual therapeutic makeup workshop * A motivational interview * A patient notebook with a personalized protocol for self-rehabilitation of the face * A video tutorial for self-rehabilitation of the face Facial self-rehabilitation sessions at home
Routine care
OTHERDelivery of a standard prescription for facial rehabilitation
Interventions
Personalized rehabilitation program of facial involvement in systemic sclerosis
Delivery of a standard prescription for facial rehabilitation
Eligibility Criteria
You may qualify if:
- Age ≥ 18 yo
- Systemic sclerosis according to the 2013 ACR/EULAR (American College of Rheumatology) classification criteria
- Systemic sclerosis with facial involvement defined by a MHISS score \> 6
- Immunosuppressive and/or anti-fibrosis treatment stable for at least 1 month
- Subject able to understand the objectives and risks of research and to give informed consent
- Subject enrolment in the health insurance scheme
You may not qualify if:
- Pregnancy
- Previous participation in a rehabilitation program of facial involvement
- Patient under legal protection
- Impossibility to give clear information of subject
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpitaux Universitaire de Strasbourg
Strasbourg, Bas-Rhin, 67300, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 22, 2021
First Posted
January 4, 2022
Study Start
October 13, 2022
Primary Completion (Estimated)
November 1, 2029
Study Completion (Estimated)
December 1, 2029
Last Updated
June 8, 2026
Record last verified: 2026-06